A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study.

Six hundred eighty assessable patients with measureable stage III M1, non-small-cell lung cancer (NSCLC) were randomized to one of five treatment arms including cisplatin, etoposide (VP-16) +/- methylglyoxal bisguanylhydrazone (MGBG; PVp, PVpM); cisplatin, vinblastine (PVe); or PVe alternating with vinblastine, mitomycin (PVeMi); or fluorouracil, vincristine, mitomycin/cyclophosphamide, doxorubicin, cisplatin (FOMi/CAP). The overall response rate was 20% with 3% complete responses and 17% partial remissions. The duration of these responses was not statistically different by treatment regimen and varied from 2.7 months to 5.0 months. The overall median survival for all patients was 5.3 months and is not different by treatment. Toxicity was greater in PVpM. The similarity of results for response, duration of response, and survival does not establish the superiority of any of these platinum-based regimens for standard clinical usage.

[1]  R. Livingston.  Treatment of advanced non-small cell lung cancer: the Southwest Oncology Group experience. , 1988, Seminars in oncology.

[2]  Selawry Os.  Monochemotherapy of bronchogenic carcinoma withs special reference to cell type. , 1973 .

[3]  D. Gandara,et al.  High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[5]  D. Cox.  Regression Models and Life-Tables , 1972 .

[6]  T. Miller,et al.  Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Budman,et al.  Phase II trial of mitomycin, vinblastine, and cisplatin (MVP) in non-small cell bronchogenic carcinoma. , 1983, Cancer treatment reports.

[8]  E. Casper,et al.  Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer. , 1981, Cancer Clinical Trials.

[9]  S. Crooke,et al.  Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. , 1978, Cancer treatment reports.

[10]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[11]  R. Livingston,et al.  Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: a Southwest Oncology Group Study. , 1985, Cancer treatment reports.

[12]  R. Livingston,et al.  Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Finkelstein,et al.  Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V--a randomized comparison of four cisplatin-containing regimens. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.